Literature DB >> 18578076

Hepatitis C: the juggernaut rolls on unchecked.

Morris Sherman.   

Abstract

Mesh：

Year:  2008        PMID： 18578076      PMCID： PMC2662890          DOI： 10.1155/2008/637935

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN： 0835-7900            Impact factor:   3.522


× No keyword cloud information.
  5 in total

1.  Prediction of hepatitis C burden in Canada.

Authors:  S Zou; M Tepper; S El Saadany
Journal:  Can J Gastroenterol       Date:  2000 Jul-Aug       Impact factor: 3.522

2.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

3.  Trends of hepatitis B and hepatitis C mortality in Canada, 1979-1997.

Authors:  G Pohani; S Zou; M Tepper
Journal:  Can J Public Health       Date:  2001 Jul-Aug

4.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

5.  Post-transfusion hepatitis: impact of non-A, non-B hepatitis surrogate tests. Canadian Post-Transfusion Hepatitis Prevention Study Group.

Authors:  M A Blajchman; S B Bull; S V Feinman
Journal:  Lancet       Date:  1995-01-07       Impact factor: 79.321
  5 in total
  1 in total

1.  Cost-effectiveness of screening for hepatitis C in Canada.

Authors:  William W L Wong; Hong-Anh Tu; Jordan J Feld; Tom Wong; Murray Krahn
Journal:  CMAJ       Date:  2015-01-12       Impact factor: 8.262
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.